Top

The Journal of Prevention of Alzheimer's Disease

Published in:

Open Access 01-10-2021 | Alzheimer's Disease | Special Article

Aducanumab: Appropriate Use Recommendations

Authors: Jeffrey Cummings, P. Aisen, L. G. Apostolova, A. Atri, S. Salloway, M. Weiner

Published in: The Journal of Prevention of Alzheimer's Disease | Issue 4/2021

Abstract

Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer’s disease (AD). Clinicians require guidance on the appropriate use of this new therapy. An Expert Panel was assembled to construct Appropriate Use Recommendations based on the participant populations, conduct of the pivotal trials of aducanumab, updated Prescribing Information, and expert consensus. Aducanumab is an amyloid-targeting monoclonal antibody delivered by monthly intravenous infusions. The pivotal trials included patients with early AD (mild cognitive impairment due to AD and mild AD dementia) who had confirmed brain amyloid using amyloid positron tomography. The Expert Panel recommends that use of aducanumab be restricted to this population in which efficacy and safety have been studied. Aducanumab is titrated to a dose of 10 mg/kg over a 6-month period. The Expert Panel recommends that the aducanumab be titrated to the highest dose to maximize the opportunity for efficacy. Aducanumab can substantially increase the incidence of amyloid-related imaging abnormalities (ARIA) with brain effusion or hemorrhage. Dose interruption or treatment discontinuation is recommended for symptomatic ARIA and for moderate-severe ARIA. The Expert Panel recommends MRIs prior to initiating therapy, during the titration of the drug, and at any time the patient has symptoms suggestive of ARIA. Recommendations are made for measures less cumbersome than those used in trials for the assessment of effectiveness in the practice setting. The Expert Panel emphasized the critical importance of engaging in a process of patient-centered informed decision-making that includes comprehensive discussions and clear communication with the patient and care partner regarding the requirements for therapy, the expected outcome of therapy, potential risks and side effects, and the required safety monitoring, as well as uncertainties regarding individual responses and benefits.

U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. Aducanumab. Reference ID 4822820 2021; Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178.

U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs — Aducanumab. Reference ID 4807032. 2021

Arndt JW, Qian F, Smith BA, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta. Sci Rep. 2018;8:6412; DOI: https://doi.org/10.1038/s41598-018-24501-0.PubMedPubMedCentralCrossRef

Haeberlein SB, Von Hehn C, Tian Y, et al., editors. EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease. Clinical Trials on Alzheimer’s Disease; 2019 December 5, 2019; San Diego, CA.

Sandrock A. Aducanumab for the treatment of Alzheimer’s disease. U.S. Food & Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee. November 6, 2020.

Atri A. The Alzheimer’s disease clinical spectrum: diagnosis and management. Med Clin North Am. 2019;103:263–293; DOI: https://doi.org/10.1016/j.mcna.2018.10.009.PubMedCrossRef

McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269; DOI: https://doi.org/10.1016/j.jalz.2011.03.005.PubMedPubMedCentralCrossRef

Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–279; DOI: https://doi.org/10.1016/j.jalz.2011.03.008.PubMedPubMedCentralCrossRef

Food and Drug Administration. Early Alzheimer’s Disease: Developing Drugs for Treatment Guidance for Industry. U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). February, 2018.

10.

Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–2414; DOI: https://doi.org/10.1212/wnl.43.11.2412-a.PubMedCrossRef

11.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198; DOI: https://doi.org/10.1016/0022-3956(75)90026-6.PubMedCrossRef

12.

Feeney J, Savva GM, O’Regan C, King-Kallimanis B, Cronin H, Kenny RA. Measurement error, reliability, and minimum detectable change in the Mini-Mental State Examination, Montreal Cognitive Assessment, and Color Trails Test among community living middle-aged and older adults. J Alzheimers Dis. 2016;53:1107–1114; DOI: https://doi.org/10.3233/JAD-160248.PubMedCrossRef

13.

Hensel A, Angermeyer MC, Riedel-Heller SG. Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination. J Neurol Neurosurg Psychiatry. 2007;78:1298–1303; DOI: https://doi.org/10.1136/jnnp.2006.109074.PubMedPubMedCentralCrossRef

14.

Tombaugh TN. Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS. Arch Clin Neuropsychol. 2005;20:485–503; DOI: https://doi.org/10.1016/j.acn.2004.11.004.PubMedCrossRef

15.

Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016;537:50–56; DOI: https://doi.org/10.1038/nature19323.PubMedCrossRef

16.

Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699; DOI: https://doi.org/10.1111/j.1532-5415.2005.53221.x.PubMedCrossRef

17.

Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ, Alzheimer’s Disease Neuroimaging I. Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr. 2015;15:107; DOI:https://doi.org/10.1186/s12877-015-0103-3.PubMedPubMedCentralCrossRef

18.

Jak AJ, Preis SR, Beiser AS, et al. Neuropsychological criteria for mild cognitive impairment and dementia risk in the Framingham Heart Study. J Int Neuropsychol Soc. 2016;22:937–943; DOI:https://doi.org/10.1017/S1355617716000199.PubMedPubMedCentralCrossRef

19.

Deardorff WJ, Feen E, Grossberg GT. The use of cholinesterase inhibitors across all stages of Alzheimer’s disease. Drugs Aging. 2015;32:537–547; DOI: https://doi.org/10.1007/s40266-015-0273-x.PubMedCrossRef

20.

Sevigny J, Suhy J, Chiao P, et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis Assoc Disord. 2016;30:1–7; DOI: https://doi.org/10.1097/WAD.0000000000000144.PubMedCrossRef

21.

Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9:e-1–16; DOI: https://doi.org/10.1016/j.jalz.2013.01.002.CrossRef

22.

Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275–283; DOI: https://doi.org/10.1001/jama.2010.2008.PubMedPubMedCentralCrossRef

23.

Seibyl J, Catafau AM, Barthel H, et al. Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: results from a phase-3 study. J Nucl Med. 2016;57:900–906; DOI: https://doi.org/10.2967/jnumed.115.161927.PubMedCrossRef

24.

Buckley CJ, Sherwin PF, Smith AP, Wolber J, Weick SM, Brooks DJ. Validation of an electronic image reader training programme for interpretation of [18F]flutemetamol beta-amyloid PET brain images. Nucl Med Commun. 2017;38:234–241; DOI: https://doi.org/10.1097/MNM.0000000000000633.PubMedCrossRef

25.

Shaw LM, Arias J, Blennow K, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease. Alzheimers Dement. 2018;14:1505–1521; DOI: https://doi.org/10.1016/j.jalz.2018.07.220.PubMedCrossRef

26.

Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF amyloid beta (Abeta) 42/40 ratio in the diagnosis of Alzheimer’s disease. Alzheimers Res Ther. 2019;11:34; DOI: https://doi.org/10.1186/s13195-019-0485-0.PubMedPubMedCentralCrossRef

27.

Skillback T, Farahmand BY, Rosen C, et al. Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. Brain. 2015;138:2716–273; DOI: https://doi.org/10.1093/brain/awv181.PubMedCrossRef

28.

van Harten AC, Wiste HJ, Weigand SD, et al. Detection of Alzheimer’s disease using ELECSYS amyloid-beta 1–42, p-tau and t-tau assays. Alzheimer Dement. 2021;In Press

29.

Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85:1240–1249; DOI: https://doi.org/10.1212/WNL.0000000000001991.PubMedPubMedCentralCrossRef

30.

Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512–519; DOI: https://doi.org/10.1002/ana.20730.PubMedCrossRef

31.

Palmqvist S, Mattsson N, Hansson O, Alzheimer’s Disease Neuroimaging I. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain. 2016;139:1226–1236; DOI: https://doi.org/10.1093/brain/aww015.PubMedPubMedCentralCrossRef

32.

Hampel H, Shaw LM, Aisen P, et al. State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer’s disease. Alzheimers Dement. 2021;Online ahead of print:DOI: https://doi.org/10.1002/alz.12372.

33.

Jack CR, Jr., Knopman DS, Chetelat G, et al. Suspected non-Alzheimer disease pathophysiology—concept and controversy. Nat Rev Neurol. 2016;12:117–124; DOI: https://doi.org/10.1038/nrneurol.2015.251.PubMedPubMedCentralCrossRef

34.

Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286–1294; DOI: https://doi.org/10.1001/jama.2019.2000.PubMedPubMedCentralCrossRef

35.

Sperling RA, Jack CR, Jr., Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367–385; DOI: https://doi.org/10.1016/j.jalz.2011.05.2351.PubMedPubMedCentralCrossRef

36.

VandeVrede L, Gibbs DM, Koestler M, et al. Symptomatic amyloid-related imaging abnormalities in an APOE epsilon4/epsilon4 patient treated with aducanumab. Alzheimers Dement (Amst). 2020;12:e12101; DOI: https://doi.org/10.1002/dad2.12101.PubMedPubMedCentral

37.

Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med. 2009;361:245–254; DOI: https://doi.org/10.1056/NEJMoa0809578.PubMedPubMedCentralCrossRef

38.

Langlois CM, Bradbury A, Wood EM, et al. Alzheimer’s Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement (N Y). 2019;5:705–716; DOI: https://doi.org/10.1016/j.trci.2019.09.013.CrossRef

39.

Flather M, Delahunty N, Collinson J. Generalizing results of randomized trials to clinical practice: reliability and cautions. Clin Trials. 2006;3:508–512; DOI: https://doi.org/10.1177/1740774506073464.PubMedCrossRef

40.

Bodilsen J, Mariager T, Vestergaard HH, et al. Association of lumbar puncture with spinal hematoma in patients with and without coagulopathy. JAMA. 2020;324:1419–1428; DOI: https://doi.org/10.1001/jama.2020.14895.PubMedPubMedCentralCrossRef

41.

Mayo Clinic. Clinical Trials. 221AD301 Phase 3 study of aducanumab (BIIB037) in early Alzheimer’s disease [Available from: https://www.mayo.edu/research/clinical-trials/cls-20179704.

42.

Goos JD, van der Flier WM, Knol DL, et al. Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging. Stroke. 2011;42:1894–1900; DOI: https://doi.org/10.1161/STROKEAHA.110.599837.PubMedCrossRef

43.

Cummings J, Fox N. Defining disease modifying therapy for Alzheimer’s disease. J Prev Alzheimers Dis. 2017;4:109–115; DOI: https://doi.org/10.14283/jpad.2017.12.PubMedPubMedCentral

44.

Cartz-Piver L, Polin C, Diebolt C, et al. Therapeutic patient education in Alzheimer’s disease and related disorders: Clinical experience and perspectives. Rev Neurol (Paris). 2020;176:200–207; DOI: https://doi.org/10.1016/j.neurol.2019.07.028.PubMedCrossRef

45.

Cuevas AG, O’Brien K, Saha S. African American experiences in healthcare: “I always feel like I’m getting skipped over”. Health Psychol. 2016;35:987–995; DOI: https://doi.org/10.1037/hea0000368.PubMedCrossRef

46.

Mehta KM, Yin M, Resendez C, Yaffe K. Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease. Neurology. 2005;65:159–162; DOI: https://doi.org/10.1212/01.wnl.0000167545.38161.48.PubMedCrossRef

47.

Gleason CE, Dowling NM, Benton SF, Kaseroff A, Gunn W, Edwards DF. Common sense model factors affecting African Americans’ willingness to consult a healthcare provider regarding symptoms of mild cognitive impairment. Am J Geriatr Psychiatry. 2016;24:537–546; DOI: https://doi.org/10.1016/j.jagp.2015.08.005.PubMedCrossRef

48.

Cuevas AG, O’Brien K, Saha S. What is the key to culturally competent care: Reducing bias or cultural tailoring? Psychol Health. 2017;32:493–507; DOI: https://doi.org/10.1080/08870446.2017.1284221.PubMedPubMedCentralCrossRef

49.

Bechten A, Wattjes MP, Purcell DD, et al. Validation of an MRI rating scale for amyloid-related imaging abnormalities. J Neuroimaging. 2017;27:318–325; DOI: https://doi.org/10.1111/jon.12422.PubMedCrossRef

50.

Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141:1356–1364; DOI: https://doi.org/10.1176/ajp.141.11.1356.PubMedCrossRef

51.

Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33–39PubMedCrossRef

52.

Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314; DOI: https://doi.org/10.1212/wnl.44.12.2308.PubMedCrossRef

53.

Tractenberg RE, Yumoto F, Jin S, Morris JC. Sample size requirements for training to a kappa agreement criterion on clinical dementia ratings. Alzheimer Dis Assoc Disord. 2010;24:264–268; DOI: https://doi.org/10.1097/WAD.0b013e3181d489c6.PubMedPubMedCentralCrossRef

54.

Sun N, Mormino EC, Chen J, Sabuncu MR, Yeo BTT, Alzheimer’s Disease Neuroimaging I. Multi-modal latent factor exploration of atrophy, cognitive and tau heterogeneity in Alzheimer’s disease. Neuroimage. 2019;201:116043; DOI: https://doi.org/10.1016/j.neuroimage.2019.116043.PubMedCrossRef

55.

Giorgio J, Landau SM, Jagust WJ, Tino P, Kourtzi Z, Alzheimer’s Disease Neuroimaging I. Modelling prognostic trajectories of cognitive decline due to Alzheimer’s disease. Neuroimage Clin. 2020;26:102199; DOI: https://doi.org/10.1016/j.nicl.2020.102199.PubMedPubMedCentralCrossRef

56.

Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability of the AD8 informant interview in dementia. Neurology. 2006;67:1942–1948; DOI: https://doi.org/10.1212/01.wnl.0000247042.15547.eb.PubMedCrossRef

57.

Galvin JE, Roe CM, Powlishta KK, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65:559–564; DOI: https://doi.org/10.1212/01.wnl.0000172958.95282.2a.PubMedCrossRef

58.

Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233–239; DOI: https://doi.org/10.1176/jnp.12.2.233.PubMedCrossRef

59.

Pfeffer RI, Kurosaki TT, Harrah CH, Jr., Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323–329; DOI: https://doi.org/10.1093/geronj/37.3.323.PubMedCrossRef

60.

Kaur N, Belchior P, Gelinas I, Bier N. Critical appraisal of questionnaires to assess functional impairment in individuals with mild cognitive impairment. Int Psychogeriatr. 2016;28:1425–1439; DOI: https://doi.org/10.1017/S104161021600017X.PubMedCrossRef

61.

Liu J, Hlayka J, Hillestad R, Mattke S. Assessing the preparedness of the US health care infrastructure for an Alzeimer’s treatment. RAND Corporation, Los Angeles, 2017 (www.rand.org/t/RR2272

62.

Reuben DB, Tan ZS, Romero T, Wenger NS, Keeler E, Jennings LA. Patient and caregiver benefit from a comprehensive dementia care program: 1-year results from the UCLA Alzheimer’s and Dementia Care Program. J Am Geriatr Soc. 2019;67:2267–2273; DOI: https://doi.org/10.1111/jgs.16085.PubMedPubMedCentralCrossRef

63.

Reuben DB, Gill TM, Stevens A, et al. D-CARE: The Dementia Care Study: design of a pragmatic trial of the effectiveness and cost effectiveness of health system-based versus community-based dementia care versus usual dementia care. J Am Geriatr Soc. 2020;68:2492–2499; DOI: https://doi.org/10.1111/jgs.16862.PubMedCrossRefPubMedCentral

64.

Callahan CM, Boustani MA, Weiner M, et al. Implementing dementia care models in primary care settings: The Aging Brain Care Medical Home. Aging Ment Health. 2011;15:5–12; DOI: https://doi.org/10.1080/13607861003801052.PubMedPubMedCentralCrossRef

65.

Thorpe CT, Fowler NR, Harrigan K, et al. Racial and ethnic differences in initiation and discontinuation of antidementia drugs by medicare beneficiaries. J Am Geriatr Soc. 2016;64:1806–1814; DOI: https://doi.org/10.1111/jgs.14403.PubMedPubMedCentralCrossRef

66.

Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367:795–804; DOI: https://doi.org/10.1056/NEJMoa1202753.PubMedPubMedCentralCrossRef

67.

Shepherd C, McCann H, Halliday GM. Variations in the neuropathology of familial Alzheimer’s disease. Acta Neuropathol. 2009;118:37–52; DOI: https://doi.org/10.1007/s00401-009-0521-4.PubMedCrossRef

68.

Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019;15:135–147; DOI: https://doi.org/10.1038/s41582-018-0132-6.PubMedPubMedCentralCrossRef

69.

Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down’s syndrome. Lancet Neurol. 2016;15:622–636; DOI: https://doi.org/10.1016/S1474-4422(16)00063-6.PubMedCrossRef

70.

Paterson RW, Toombs J, Slattery CF, et al. Dissecting IWG-2 typical and atypical Alzheimer’s disease: insights from cerebrospinal fluid analysis. J Neurol. 2015;262:2722–2730; DOI: https://doi.org/10.1007/s00415-015-7904-3.PubMedCrossRef

71.

Graff-Radford J, Yong KXX, Apostolova LG, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 2021;20:222–234; DOI: https://doi.org/10.1016/S1474-4422(20)30440-3.PubMedCrossRefPubMedCentral

72.

McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100; DOI: https://doi.org/10.1212/WNL.0000000000004058.PubMedPubMedCentralCrossRef

73.

Orad RI, Shiner T. Differentiating dementia with Lewy bodies from Alzheimer’s disease and Parkinson’s disease dementia: an update on imaging modalities. J Neurol. 2021; DOI: https://doi.org/10.1007/s00415-021-10402-2.

74.

Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA. 2006;295:2148–2157; DOI: https://doi.org/10.1001/jama.295.18.2148.PubMedCrossRef

75.

Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–562; DOI: https://doi.org/10.1016/j.jalz.2018.02.018.PubMedPubMedCentralCrossRef

76.

Raposo N, Planton M, Peran P, et al. Florbetapir imaging in cerebral amyloid angiopathy-related hemorrhages. Neurology. 2017;89:697–704; DOI: https://doi.org/10.1212/WNL.0000000000004228.PubMedCrossRef

77.

Greenberg SM, Cordonnier C, Schneider JA, et al. Off-label use of aducanumab for derebral amyloid angiopathy. Lancet Neurol. 2021;Epub ahead of print; https://doi.org/10.1016/S1474-4422(21)00213-1

78.

Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647–e1659; DOI: https://doi.org/10.1212/WNL.0000000000008081.PubMedPubMedCentralCrossRef

79.

Moscoso A, Grothe MJ, Ashton NJ, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum. Brain. 2021;144:325–339; DOI: https://doi.org/10.1093/brain/awaa399.PubMedCrossRef

80.

Karikari TK, Benedet AL, Ashton NJ, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol Psychiatry. 2021;26:429–442; DOI: https://doi.org/10.1038/s41380-020-00923-z.PubMedCrossRef

81.

Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Brain. 2020;143:3234–3241; DOI: https://doi.org/10.1093/brain/awaa286.PubMedPubMedCentralCrossRef

82.

Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight. 2017;2; DOI: https://doi.org/10.1172/jci.insight.93621.

83.

Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54 Suppl 1:S204–217; DOI: https://doi.org/10.1016/j.neuroimage.2010.06.020.PubMedCrossRef

84.

Thomas JA, Burkhardt HA, Chaudhry S, et al. Assessing the utility of language and voice biomarkers to predict cognitive impairment in the Framingham Heart Study Cognitive Aging Cohort Data. J Alzheimers Dis. 2020;76:905–922; DOI: https://doi.org/10.3233/JAD-190783.PubMedCrossRef

85.

Konig A, Satt A, Sorin A, et al. Automatic speech analysis for the assessment of patients with predementia and Alzheimer’s disease. Alzheimers Dement (Amst). 2015;1:112–124; DOI: https://doi.org/10.1016/j.dadm.2014.11.012.PubMedPubMedCentralCrossRef

86.

Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384:1691–1704; DOI: https://doi.org/10.1056/NEJMoa2100708.PubMedCrossRef

87.

Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron. 2014;84:608–622; DOI: https://doi.org/10.1016/j.neuron.2014.10.038.PubMedPubMedCentralCrossRef

88.

Hartley D, Blumenthal T, Carrillo M, et al. Down syndrome and Alzheimer’s disease: Common pathways, common goals. Alzheimers Dement. 2015;11:700–709; DOI: https://doi.org/10.1016/j.jalz.2014.10.007.PubMedCrossRef

Title: Aducanumab: Appropriate Use Recommendations
Authors: Jeffrey Cummings
P. Aisen
L. G. Apostolova
A. Atri
S. Salloway
M. Weiner
Publication date: 01-10-2021
Publisher: Springer International Publishing
Keywords: Alzheimer's Disease
Alzheimer's Disease
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Dementia
Dementia
Positron Emission Tomography
Mild Cognitive Impairment
Published in: The Journal of Prevention of Alzheimer's Disease / Issue 4/2021
Electronic ISSN: 2426-0266
DOI: https://doi.org/10.14283/jpad.2021.41

At a glance: The STEP trials

Springer Medicine

Aducanumab: Appropriate Use Recommendations

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

A Fay-Herriot Model for Estimating Subjective Cognitive Decline among Military Veterans

Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging

Alzheimer’s Disease Research in Japan: A Short History, Current Status and Future Perspectives toward Prevention

A UK-Wide Study Employing Natural Language Processing to Determine What Matters to People about Brain Health to Improve Drug Development: The Electronic Person-Specific Outcome Measure (ePSOM) Programme

Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review

Tauroursodeoxycholic Acid Attenuates Diet-Induced and Age-Related Peripheral Endoplasmic Reticulum Stress and Cerebral Amyloid Pathology in a Mouse Model of Alzheimer’s Disease